RET C620Y
Gene Variant Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene RET
Variant C620Y
Impact List missense
Protein Effect gain of function
Gene Variant Descriptions RET C620Y lies within the extracellular domain of the Ret protein (UniProt.org). C620Y results in constitutive dimerization of Ret, increased Ret kinase activity, and is transforming in cell culture (PMID: 9012462).
Associated Drug Resistance
Category Variants Paths

RET mutant RET act mut RET C620Y

RET mutant RET C620X RET C620Y

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_020975.6
gDNA chr10:g.43113655G>A
cDNA c.1859G>A
Protein p.C620Y
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_020975.6 chr10:g.43113655G>A c.1859G>A p.C620Y RefSeq GRCh38/hg38
NM_001406760.1 chr10:g.43113655G>A c.1859G>A p.C620Y RefSeq GRCh38/hg38
NM_001406763.1 chr10:g.43113655G>A c.1859G>A p.C620Y RefSeq GRCh38/hg38
NM_020630.7 chr10:g.43113655G>A c.1859G>A p.C620Y RefSeq GRCh38/hg38
NM_020630.5 chr10:g.43113655G>A c.1859G>A p.C620Y RefSeq GRCh38/hg38
NM_020630 chr10:g.43113655G>A c.1859G>A p.C620Y RefSeq GRCh38/hg38
NM_020975 chr10:g.43113655G>A c.1859G>A p.C620Y RefSeq GRCh38/hg38
NM_001406743.1 chr10:g.43113655G>A c.1859G>A p.C620Y RefSeq GRCh38/hg38
NM_020975.5 chr10:g.43113655G>A c.1859G>A p.C620Y RefSeq GRCh38/hg38
NM_001406744.1 chr10:g.43113655G>A c.1859G>A p.C620Y RefSeq GRCh38/hg38
NM_001406765.1 chr10:g.43113655G>A c.1859G>A p.C620Y RefSeq GRCh38/hg38
NM_001406759.1 chr10:g.43113655G>A c.1859G>A p.C620Y RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
RET C620Y lung small cell carcinoma predicted - sensitive Selpercatinib Case Reports/Case Series Actionable In a clinical case study, Retevmo (selpercatinib) treatment resulted in a partial response with rapid clinical improvement and shrinkage of brain, skin, and muscle metastases in a patient with small cell lung cancer harboring RET C620Y who remained on treatment after 6 months (PMID: 37922409). 37922409
RET C620Y medullary thyroid carcinoma sensitive Selpercatinib FDA approved - On Companion Diagnostic Actionable In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C620Y; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128). detail... detail... 32846061